Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Usage

1. Confirm the vial label reads Testosterone Propionate 100 mg/ml and inspect the solution for clarity — a pale yellow, particle-free oil indicates correct formulation integrity.
2. Swab the rubber stopper with a fresh 70% isopropyl alcohol wipe and allow it to air-dry for 10 seconds before puncture, preserving the sterile barrier across multi-dose use.
3. Draw the calculated volume using a drawing needle into a 1 ml syringe — 0.5 ml for 50 mg, 1.0 ml for 100 mg — confirming the concentration mathematics before proceeding.
4. Replace the drawing needle with a fresh, appropriately gauged injection needle (23–25G, 1–1.5 inch for intramuscular depth) to ensure sharp, atraumatic entry and optimal deposition within muscle tissue.
5. Inject into a large muscle group (gluteus medius, vastus lateralis, or deltoid), aspirate briefly, then deliver the oil slowly over 10–15 seconds to allow the depot to form correctly and maximise local absorption efficiency.
6. Rotate injection sites systematically across each administration to prevent localised tissue fibrosis and maintain consistent absorption kinetics from each depot site over the course of the cycle.

Warnings

Frequently asked questions

Why does injectable Testosterone Propionate have higher bioavailability than oral testosterone?

Injectable Testosterone Propionate bypasses the liver entirely upon absorption, avoiding the first-pass metabolic degradation that destroys the majority of any orally administered testosterone dose before it reaches systemic circulation. Intramuscular injection deposits the esterified compound directly into muscle tissue, where it enters the bloodstream via local capillaries and lymphatics — pharmacokinetic AUC data consistently place IM testosterone bioavailability above 98%, versus as low as 2–5% for oral unmodified testosterone.

What role does first-pass metabolism play in reducing oral testosterone effectiveness?

First-pass metabolism refers to the hepatic enzymatic breakdown of a substance absorbed from the gastrointestinal tract before it reaches systemic circulation. Oral testosterone passes through the portal vein to the liver, where CYP enzymes and conjugation pathways degrade most of the dose. To survive this process, oral androgens require 17-alpha alkylation — a structural modification that carries hepatotoxicity risk and alters the compound's native receptor-binding characteristics, making oral routes fundamentally inferior for bioavailability-sensitive androgen therapy.

How does the absorption pathway after intramuscular injection differ from oral administration?

After intramuscular injection, Testosterone Propionate forms a localised oil depot within muscle tissue. Plasma and tissue esterases gradually cleave the propionate ester, releasing free testosterone directly into venous and lymphatic capillaries at the injection site. This route entirely skips the gastrointestinal tract and hepatic portal system, meaning 100% of the absorbed fraction enters systemic circulation as active or ester-bound testosterone — contrasting sharply with oral dosing, where gut wall and liver catabolism intercept the majority of the dose.

How do I dose from a 10ml vial of Propha-Testosterone 100mg/ml using an insulin syringe?

At 100 mg/ml, each 0.5 ml drawn equals exactly 50 mg and 1.0 ml equals 100 mg — volumes well within the capacity of a 1 ml insulin syringe. Draw through a clean rubber stopper using a fresh needle for each administration, swabbing the stopper with 70% isopropyl alcohol before puncture. Replace the drawing needle with a fresh injection needle before administering to maintain sharpness and sterility across the vial's multi-dose use period.

How should an opened vial of Propha-Testosterone 100mg/ml 10ml be stored?

Once the rubber stopper has been punctured, store the vial upright in a cool, dark environment — ideally between 15°C and 25°C (59°F–77°F), away from direct sunlight and temperature extremes. Refrigeration is not required but permissible; if refrigerated, allow the vial to warm to room temperature before drawing to maintain solution viscosity for accurate measurement. Discard any remaining product past the manufacturer's marked expiry date or if visible particulate matter or discolouration is observed. (2) angle_used

Manufacturer

Beligas Pharmaceuticals' ester specialisation programme is most clearly demonstrated in its Testosterone Propionate line. Rather than treating all testosterone esters as interchangeable formulation templates, Beligas engineers each ester variant around its specific pharmacokinetic demands — and propionate's short-chain characteristics impose the strictest requirements. The 100 mg/ml concentration specification for Propha-Testosterone reflects a deliberate balance: concentrated enough for sub-1 ml dosing at clinically relevant amounts, yet formulated with a solvent system matched to propionate's physicochemical solubility profile rather than borrowed from longer-ester formulations. Beligas's ester-specific approach extends into quality control: because propionate-based products are drawn and administered more frequently than long-ester formats, stopper integrity, multi-puncture resilience, and endotoxin absence are tested with heightened scrutiny. Each Propha-Testosterone batch is released only after HPLC potency confirmation, sterility testing, and LAL endotoxin clearance — a three-gate release sequence applied uniformly across Beligas's short-ester injectable range. This ester-conscious manufacturing philosophy positions Beligas as a producer that understands the clinical and practical distinctions between ester classes, rather than one that applies a single quality template across all testosterone variants.